RB1 and neoplasm: To continue our preclinical evaluation of GoraVir in vivo, we used a BxPC‐3 xenograft model and tested the virus in parallel with an oncolytic derivative of HAdV‐C5 (HAdV‐C5Δ24E3) which harbours a similar deletion in the Rb‐binding domain of E1A as to increase its tumour selectivity [35].